Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer
May 2024: The Food and Drug Administration has officially approved selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of advanced or metastatic RET...
Imetelstat is approved by FDA for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia
May 2024: Imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, has been approved by the Food and Drug Administration for use in adults with...
Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma
Lisocabtagene maraleucel, a CAR T-cell therapy, has been approved by the FDA for the treatment of adults with relapsed or refractory mantle cell lymphoma. This...
Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer
May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung...
Lisocabtagene maraleucel is granted accelerated approval by FDA for follicular lymphoma
The FDA has granted accelerated approval to Lisocabtagene maraleucel for treating follicular lymphoma. This CAR T-cell therapy targets the CD19 antigen on B-cells, offering a...
Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer
Tisotumab Vedotin-tftv has been approved by the FDA for treating recurrent or metastatic cervical cancer. This antibody-drug conjugate targets tissue factor, delivering a cytotoxic agent...
Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma
Tovorafenib has received accelerated approval from the FDA for treating relapsed or refractory BRAF-altered pediatric low-grade glioma. This approval offers new hope for children facing...
Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study
CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations...
Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
Seattle Children's Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body's immune cells to target...
Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying...
Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report
Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to...
What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?
For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.